Loading…
← CockpitCompetitor Analysis › IDXX Idexx LaboratoriesOpen in the cockpit ↗

Idexx LaboratoriesIDXXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Leading maker of veterinary diagnostic tests, instruments and software for companion-animal and livestock health.

Momentum leader 94
Mkt cap
$55.0B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$443M
20-day average traded
Fwd P/E
42.9×
forward earnings
ROIC−WACC
+32.4 pp
WACC 12.7%
Hurdle
+19 pp
Req g minus delivered
Next earnings
82 days
8 Feb 2027
Close · USD$698.47
1D+1.2%
1W-0.6%
1M+25.2%
3M+28.0%
6M+26.2%
YTD+3.2%
1Y+4.4%
ATR %3.3%
Beta0.83
52w lowhigh9.3% off high

What Idexx Laboratories does

Leading maker of veterinary diagnostic tests, instruments and software for companion-animal and livestock health.

Places analyzers in veterinary clinics, then earns most revenue from the test consumables run on them and from its reference laboratories, which handle tests that clinics send out. Direct sales representatives serve clinics, with distributors for some, and software ties results into the clinic's records.

Products and services

  • Companion Animal Group (in-clinic analyzers, reference labs)
  • Water quality testing
  • Livestock/poultry diagnostics

Customers

  • Veterinary clinics
  • Reference laboratories

Where it sits in the supply chain

  • Healthcare
  • Veterinary diagnostics
  • In-clinic and reference-lab animal…

What could go right

  • Pet-ownership/spending growth
  • International vet-clinic penetration

What could go wrong

  • Slowing vet-visit volume growth
  • Competitive pricing in point-of-care diagnostics

Moat: wide (installed base, switching costs, distribution). Placed analyzer base in vet clinics locks in recurring consumables/reagent revenue.

Headquarters: Westbrook, Maine, USA · Founded: 1983 · Employees: 11,000

Named competitors

  • Zoetis ZTS
  • Heska (Mars-owned) private or unlisted
  • Antech Diagnostics (Mars) private or unlisted
  • Neogen NEOG
  • Zomedica private or unlisted

Idexx Laboratories at a glance

Size Idexx Laboratories (IDXX) is a United States Health Care company (Medical Specialties) with a market value of $55.0B, the 234th largest of 3,085 United States companies the cockpit tracks. Shares closed at $698.47 on 18 Nov 2026.

Performance Over six months the shares gained 26.2%, against +23.6% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 11.9% over the last twelve months (peer median +8.0%); the operating margin is 32.4% (peer median 21.1%).

Valuation It trades at 42.9× forward earnings against a peer median of 26.3× (2nd most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 32.4 points above its cost of capital (12.7% WACC).

Short interest Short interest is 3.0% of the free float (30 Oct 2026).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026IDXX 126Peer median 122
Six months, rebased to 100: Idexx Laboratories against the median of its 20 peers (local-currency closes).

Idexx Laboratories financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$4.66B$4.30B$3.90B$3.66B$3.37B
Revenue growth—+10%+6%+9%—
Gross profit$2.93B$2.66B$2.37B$2.19B$1.98B
EBITDA$1.67B$1.51B$1.26B$1.21B$988M
Net income$1.18B$1.06B$888M$845M$679M
Free cash flow$1.30B$1.05B$808M$773M$394M
Capital expenditure$119M$138M$131M$134M$159M
Total debt$973M$976M$987M$1.07B$1.47B

Quarterly statements and history in the cockpit →

Idexx Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%SHLMDLNBDXEWA7741BSXWATGEHCALCMTDRMD300760ELILMNDXCMWSTSTESYKIDXX6-month return →1-month return →
Up and to the right = strong over both horizons. Idexx Laboratories is the large dot.

Fundamentals: revenue growth against valuation

+5%+10%20×30×40×SHLMDLNBDXEWA7741BSXWATGEHCALCMTDRMD300760ELILMNWSTSTESYKDIMIDXXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Idexx Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%SHLMDLNBDXEWA7741BSXWATGEHCALCMTDRMD300760ELILMNDXCMWSTSTESYKDIMIDXXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Idexx Laboratories is the large dot.

Idexx Laboratories competitors and peer comparison

Head to head with its named competitors (IDXX vs ZTS vs NEOG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Idexx Laboratories IDXX$55.0B+26%+12%32%42.9×29.0%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Neogen NEOG$2.42B+25%0%0%32.6×n/a

How Idexx Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Idexx Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureIDXXPeer medianRank in peer set
1-month return+25.2%+5.6%highest of 21
6-month return+26.2%+23.6%11th highest of 21
Distance from 52-week high-9.3%-8.3%10th lowest of 21
Revenue growth (TTM)+11.9%+8.0%6th highest of 21
Operating margin32.4%21.1%2nd highest of 21
Forward P/E42.9×26.3×2nd most expensive of 21
Growth the price implies (Req g, 7 yrs)29.0%15.0%3rd most demanding of 21
Growth delivered (Del g)+9.7%+8.3%9th highest of 21
Hurdle (Req g minus delivered)+19.2 pp+3.9 pp4th most demanding of 21
ROIC minus cost of capital+32.4 pp+3.9 pp4th highest of 21
EV / EBITDA33.5×19.1×2nd most expensive of 20
Net debt / EBITDA0.5×1.5×6th least indebted of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%

Questions

Who are Idexx Laboratories's main competitors?
Named competitors: Zoetis (ZTS), Heska (Mars-owned) (private or unlisted), Antech Diagnostics (Mars) (private or unlisted), Neogen (NEOG), Zomedica (private or unlisted). The cockpit's measured peer set (industry) also includes Siemens Healthineers (SHL.DE), Medline (MDLN), Becton Dickinson (BDX), Edwards Lifesciences (EW), Agilent Technologies (A), Hoya (7741.T).
Is Idexx Laboratories expensive compared with its peers?
On forward p/e it trades at 42.9× against a peer median of 26.3×, 2nd most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Idexx Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +26.2% against +23.6% for the median peer; over one year +4.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.